louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04985500: ESP/PIF for Sternotomy
Official title: Erector Spinae Plane Block vs. Pecto-intercostal Fascial Plane Block vs. Control for Sternotomy: A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Cardiac Surgery
Sternotomy
Keywords: ESP Block
PIF Block
Cardiac Surgery
Sternotomy
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
First posted: 2021-08-02
Enrollment: 225
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Patients will be assigned randomly using a computer-generated table of numbers to one of the three groups: 1) ESP group, 2) PIF group, or 3) no block group.
Primary purpose: TREATMENT

Brief summary: This is a randomized study. The purpose of this study is to evaluate the effect of post-surgical pain control of two types of peripheral nerve blocks, specifically erector spinal plane (ESP) block and pecto-intercostal fascial (PIF) plane block.

90 subjects, from 18-85 years of age, undergoing cardiac surgery with median sternal incision will be enrolled at Mount Sinai Morningside Hospital Center. Study participation will last from the time of pre-operative evaluation to 72 hours after surgery. Subjects will be randomly assigned to receive 1 of the 3 different regimens at the beginning of surgery. Opioid consumption and pain scores after surgery will be evaluated. Though unlikely, risks include systemic absorption of local anesthetic, which can result in both central nervous system and cardiac toxicity.


Eligibility criteria: Inclusion Criteria:

* Adults 18-85 years old
* Scheduled to undergo cardiac procedures involving sternotomy
* All genders

Exclusion Criteria:

* ASA class V
* Urgent or emergent surgery
* Contraindications to administration of local anesthesia (e.g. local anesthetic allergy)
* History of substance abuse or chronic opioid use
* Patient refusal or inability to consent

Primary outcomes:
measure: Opioid Consumption during first 24 hours post-op
timeFrame: Post-operative 24 hours
measure: Opioid Consumption during first 48 hours post-op
timeFrame: Post-operative 48 hours
measure: Opioid Consumption during first 72 hours post-op
timeFrame: Post-operative 72 hours
Secondary outcomes:
measure: Visual Analogue Score (VAS) Pain Score post-op 24 hours
timeFrame: Post-operative 24 hours
measure: Visual Analogue Score (VAS) Pain Score post-op 48 hours
timeFrame: Post-operative 48 hours
measure: Visual Analogue Score (VAS) Pain Score post-op 72 hours
timeFrame: Post-operative 72 hours
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai Morningside Hospital
state: New York
Study officials:
affiliation: Mount Sinai West and Morningside Hospitals
name: Ali Shariat, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Mount Sinai West and Morningside Hospitals
name: Himani Bhatt, D.O.
role: STUDY_DIRECTOR
affiliation: Mount Sinai West and Morningside Hospitals
name: Shenghao Fang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04474600: Anesthesia and Acute Kidney Injury After Nephrectomy
Official title: The Influence of Type of Anesthesia on Postoperative Renal Function After Nephrectomy: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nephrectomy
Keywords: Anesthesia
Propofol
Inhaled anesthetics
Acute kidney injury
Nephrectomy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2020-07-17
Enrollment: 324
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study investigates the influence of type of anesthesia on postoperative renal dysfunction in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics using desflurane.

Detailed description: Nephrectomy is considered as a standard therapy for renal cell carcinoma, but it can cause postoperative renal dysfunction, such as acute kidney injury and chronic kidney disease. Therefore, it is imperative to identify modifiable risk factors for postoperative acute kidney injury after nephrectomy in advance. According to a recent retrospective study, total intravenous anesthesia using propofol is significantly associated with lower incidence of acute kidney injury after nephrectomy, compared to the inhalation anesthesia. However, there is no prospective study which investigates the influence of type of anesthesia on postoperative renal function after nephrectomy. Therefore, in the present study, we aimed to investigate the influence of type of anesthesia on acute kidney injury after nephrectomy by performing randomized controlled study.

Eligibility criteria: Inclusion Criteria:

* Adults patients scheduled for elective open nephrectomy

Exclusion Criteria:

* Patients diagnosed with acute kidney injury preoperatively
* Patients who have chronic kidney disease over stage 5 (estimated glomerular filtration rate \[eGFR\] \<15 ml/kg/1.73m2) or have regular hemodialysis preoperatively

Primary outcomes:
measure: the incidence of acute kidney injury
timeFrame: during the postoperative seven days
Secondary outcomes:
measure: serum creatinine
timeFrame: postoperative day 1, 3, 14
measure: estimated glomerular filtration rate
timeFrame: postoperative day 1, 3, 14
measure: biomarker of renal injury
timeFrame: postoperative day 1, 3, 14
measure: the incidence of postoperative complications
timeFrame: during the postoperative two weeks
measure: Length of hospital stay
timeFrame: during the postoperative two weeks
measure: Length of intensive care unit stay
timeFrame: during the postoperative two weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02360800: Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Redo Cardiac Surgery
Official title: Randomized Prospective Comparison of Tisseel Or Control to Diminish Blood Loss After Redo Redo Cardiac Surgery: the Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemorrhage
Keywords: Bleeding
Heart Surgery
Reoperation
Lead sponsor: Cardiochirurgia E.H.
Sponsor class: OTHER
First posted: 2015-02-11
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bleeding after redo cardiac surgery is a common, unresolved and consequences-heavy event as per present day. Tisseel (Baxter inc) sprayed on the already hemostased mediastinum jut before closing seems a promising technique to radically diminish bleeding.

This study aims to verify this efficacy volume in chest drains) and possibly the consensual blood transfusion lessening.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing any kind of redo cardiac surgery with ati least one previous sternotomy

Exclusion Criteria:

* None

Primary outcomes:
measure: Bleeding (Amount of blood (ml) collected in chest drainage)
timeFrame: first 24 hours after surgery
Secondary outcomes:
measure: Allogeneic blood Sparing (Amount of Allogeneic Blood units (number) transfused in the first 4 days after surgery)
timeFrame: 4 days after surgery
Other outcomes:
Locations:
city: Rome
country: Italy
facility: European Hospital
state: Lazio
Study officials:
References:
Clinical trial NCT00002100: Phase I/II Study of Curdlan Sulfate
Official title: Phase I/II Study of Curdlan Sulfate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: Acquired Immunodeficiency Syndrome
AIDS-Related Complex
curdlan sulfate
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

Detailed description: In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)

Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV seropositivity.
* No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy.
* CD4 count \< 500 cells/mm3.
* No critical illness that would shorten life expectancy to \< 16 weeks.

Exclusion Criteria

Concurrent Medication:

Excluded:

* Antiretroviral or other experimental therapies.
* Anticoagulants.
* Steroids.
* Cytotoxic or immunosuppressive agents.

Concurrent Treatment:

Excluded:

* Radiotherapy.

Patients with the following prior condition are excluded:

History of heparin sensitivity.

Prior Medication:

Excluded within 1 month prior to study entry:

* Antiretroviral or other experimental therapies.
* Anticoagulants.
* Steroids.
* Cytotoxic or immunosuppressive agents.

Prior Treatment:

Excluded:

* Radiotherapy within 1 month prior to study entry. Active IV drug abuse.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: ViRx Inc
state: California
Study officials:
References:
citation: Gordon M, Guralnik M, Kaneko Y, Mimura T, Baker M, Lang W. A phase I study of curdlan sulfate--an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes. J Med. 1994;25(3-4):163-80.
Clinical trial NCT03347500: Microfluidic Organotypic Model for Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients
Official title: Development of a Microfluidic Organotypic Model to Evaluate Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoarthritis
Lead sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Sponsor class: OTHER
First posted: 2017-11-20
Enrollment: 88
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: OA patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi

Brief summary: Osteoarthritis (OA) is the fastest growing cause of disability worldwide due to population ageing and increasing obesity incidence. Obese individuals have a higher risk of OA insurgence and severe progression due to several risk factors, including their systemic inflammation state and superior migratory ability of monocytes. In the present project we aim at the development of a novel 3D microfluidic organotypic model resembling the joint to investigate the migration ability of monocytes from obese and non-obese OA patients.

We hypothesize that monocytes from obese OA patients display superior migration ability and a specific pattern of chemokine surface receptors compared to monocytes from non-obese OA patients. We also hypothesize that these features lead to a superior infiltration of monocytes/macrophages to the synovial membrane in obese OA patients. Based on this, our main aim will be to highlight differences between Mo from obese and non-obese OA patients in terms of surface receptors and migration ability in a microfluidic organotypic model.


Eligibility criteria: Inclusion criteria

Obese OA patients

* Subscription of informed consent
* BMI ≥ 30
* age between 60-80 years included
* Kelgrenn-Lawrence equal or superior to grade III
* presence of synovitis
* patients undergoing knee replacement
* suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice

Non-obese OA patients

* Subscription of informed consent
* BMI ≤ 28
* age between 60-80 years included
* Kelgrenn-Lawrence equal or superior to grade III
* presence of synovitis
* patients undergoing knee replacement
* suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice

Exclusion criteria

Obese OA patients - HCV, HIV, HBV, TPHA infection

Non-obese OA patients

- HCV, HIV, HBV, TPHA infection

Primary outcomes:
measure: Chemokine receptor expression
timeFrame: 24 hours
Secondary outcomes:
measure: Monocyte transendothelial migration
timeFrame: 48 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05393700: Effects of Early Sleep After Action Observation Therapy on Balance in Elderly
Official title: Effects of Early Sleep After Action Observation Therapy on Balance in Elderly
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Old Age; Debility
Balance; Distorted
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2022-05-26
Enrollment: 45
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims at investigating the effects of an early sleep window after Action Observation Therapy (AOT) on balance in elderly. Forty-five healthy-like elderly will be enrolled and randomized into 3 groups (AOT-sleep, AOT-control and Control) performing a 3-week AOT. AOT-sleep and AOT-control will be asked to watch video-clips showing motor contents before sleeping or at least 12 hours before sleeping, respectively, whereas Control will be asked to watch landascape video-clips before sleeping. Participants will be assessed before and after training and at 1 month follow-up for balance outcomes.


Eligibility criteria: Inclusion Criteria:

* Ability to walk for at least 100 meters with no assistance or aids

Exclusion Criteria:

* Musculoskeletal disorders able to affect balance
* Traumas and/or injuries and/or surgery at the level of the lower limbs, spine in the previous year
* Sleep disorders
* Drugs able to affect sleep
* Dementia or cognitive decline (MCI)
* Psychiatric or neurological disorders

Primary outcomes:
measure: Changes in Lower Quarter Y-Balance Test
timeFrame: At baseline, 3 weeks and 1 month after the training end
measure: Changes in 10-Meter Walking Test
timeFrame: At baseline, 3 weeks of training and 1 month after the training end
measure: Changes in Timed Up and Go Test
timeFrame: At baseline, 3 weeks of training and 1 month after the training end
measure: Changes in Four Step Square Test
timeFrame: At baseline, 3 weeks of training and 1 month after the training end
Secondary outcomes:
measure: Changes in center of pressure parameters
timeFrame: At baseline, 3 weeks of training and 1 month after the training end
measure: Changes in Fall Efficacy Scale
timeFrame: At baseline, 3 weeks of training and 1 month after the training end
measure: Pittsburg Quality Sleep Index
timeFrame: 3 weeks
measure: Kinesthetic and Visual Imagery Questionnaire
timeFrame: At baseline
measure: Morningness Eveningness Scale
timeFrame: At baseline
measure: Euro Quality of Life - 5 dimensions
timeFrame: At baseline
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00819000: Therapy Optimization in Multiple Sclerosis (MS)
Official title: TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: Specialty Pharmacy
Therapy Management
Medication Compliance
Medication Adherence
Medication Persistence
Health Outcomes
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2009-01-08
Enrollment: 2878
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies

Brief summary: The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.


Eligibility criteria: Inclusion Criteria:

* Male or female, 18 years of age or older, with a diagnosis of MS.
* Being treated with Glatiramer Acetate (GA) or (IFN)-β
* Receiving therapy from a participating Specialty Pharmacy

Exclusion Criteria:

* Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
* Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
* Unlikely to be able to participate for the full two years of the study

Primary outcomes:
measure: Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes
timeFrame: 12 months and 24 months
Secondary outcomes:
measure: Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes
timeFrame: 12 months and 24 months
Other outcomes:
Locations:
city: Swartz Creek
country: United States
facility: Teva Investigational Site
state: Michigan
city: Columbus
country: United States
facility: Teva Investigational Site
state: Ohio
city: Carnegie
country: United States
facility: Teva Investigational Site
state: Pennsylvania
Study officials:
affiliation: Teva Neuroscience, Inc.
name: MerriKay Oleen-Burkey, PhD
role: STUDY_CHAIR
affiliation: Neurologic Center of South Florida
name: Howard Zwibel, MD
role: STUDY_DIRECTOR
References:
citation: Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015 Jan;4(1):75-82. doi: 10.1016/j.msard.2014.09.214. Epub 2014 Oct 7.
citation: Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, Tullman MJ, Zwibel H. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol. 2014 Mar 13;14:49. doi: 10.1186/1471-2377-14-49.
Clinical trial NCT06682000: Efficacy and Safety of DWC202404 and DWC202314 in Patients with Hypertension
Official title: A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Hypertension
Essential Hypertension
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2024-11-12
Enrollment: 186
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy


Eligibility criteria: Inclusion Criteria:

* Average systolic blood pressure (MSSBP) measured at the time of screening meet the following criteria (a) If anti-hypertensive drugs are not being administered: 140 mmHg ≤ MSSBP \< 180 mmHg (b) If anti-hypertensive drugs are being administered: 130 mmHg ≤ MSSBP \< 180 mmHg

Exclusion Criteria:

* If the blood pressure measured at the time of screening and randomization is MSDBP ≥ 110 mmHg
* Those whose blood pressure differences measured on both arms at the time of screening are MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg

Primary outcomes:
measure: Change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02132000: Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Breast Cancer Patients in Premenopausal
Estrogen and/or Progesterone Receptor Positive
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2014-05-06
Enrollment: 3036
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Breast cancer
* Received standard treatment (chemotherapy, operation, or radiotherapy)
* premenopausal
* estrogen and/or progesterone receptor positive

Exclusion Criteria:

* Metastatic tumors
* During pregnancy or lactation

Primary outcomes:
measure: survival outcomes: disease free survival
timeFrame: up to 5 years
measure: 5-year overall survival
timeFrame: up to 5 years
Secondary outcomes:
measure: side effects effects of therapies
timeFrame: Follow-up period,up to 5 years
measure: Incidence of adverse events
timeFrame: follow-up period, up to 5 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Breast cancer center of Sun Yat-sen Memorial Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT02915770: Clinical Application of Cholangiojejunostomy in the Surgical Treatment of Cholelithiasis With Moderate Dilatation of Common Bile Duct
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cholangiojejunostomy
Cholelithiasis
Keywords: Moderate dilatation of common bile duct
Lead sponsor: Southwest Hospital, China
Sponsor class: OTHER
First posted: 2016-09-27
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the clinical application of cholangiojejunostomy in the surgical treatment of cholelithiasis with Moderate dilatation of common bile duct. Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage, while the other half will receive hepatectomy and T-tube Drainage.


Eligibility criteria: Inclusion Criteria:

* Hepatic bile duct stone disease, need surgery
* No residual stones in the operation
* Extrahepatic bile duct dilatation, 15-30 mm in diam.
* No relaxation or stenosis of the sphincter of Oddi

Exclusion Criteria:

* Patient involuntary
* Surgical treatment can not be performed because of various reasons.
* Intrahepatic and extrahepatic bile duct stones can not be taken away
* with other biliary tract diseases, such as bile duct cancer
* Oddi sphincter relaxation or stenosis
* loss to follow-up

Primary outcomes:
measure: Recurrence of bile duct stones
timeFrame: 2-3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University
state: Chongqing
Study officials:
References: